[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569766":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":28,"locations":37,"responsibleParty":125,"collaborators":129,"id":150,"slug":151,"hasResults":152,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":158,"sex":159,"minAge":160,"maxAge":161,"enrollmentInfo":162,"targetDuration":10,"studyType":165,"phases":10,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":186},{"fullName":5,"class":6},"Swiss Tropical & Public Health Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"arPZQ distributed through Platform 1 (NTD programmes)",null,"Preschool-aged children (24 to 59 months of age) of villages preselected to receive a single oral dose of 50mg\u002Fkg or 60mg\u002Fkg (depending on country) arpraziquantel as part of the routine schistosomiasis mass drug administration campaigns led by the national NTD programmes.",[13],"Drug: Arpraziquantel 150mg dispersible tablet",{"label":15,"type":10,"description":16,"interventionNames":17},"arPZQ distributed through Platform 2 (child health days\u002Fnutrition programmes)","Preschool-aged children (24 to 59 months of age) of villages preselected to receive a single oral dose of 50mg\u002Fkg or 60mg\u002Fkg (depending on country) arpraziquantel as part of the routine vitamin A distribution\u002Fchild health days campaigns led by the national nutrition programmes.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DRUG","Arpraziquantel 150mg dispersible tablet","Arpraziquantel 150mg dispersible tablets given as single oral dose of 50mg\u002Fkg (in Kenya and Uganda; for Schistosoma mansoni infection) or 60mg\u002Fkg (in Côte d'Ivoire; for mixed infections with S. mansoni \u002F S. haematobium) using weight-based dosing tables as detailed in the summary of product characteristics.",[9,15],[25],{"name":26,"affiliation":5,"role":27},"Peter Steinmann, PhD PD","PRINCIPAL_INVESTIGATOR",[29,33],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","+41 61 284 82 18","peter.steinmann@swisstph.ch",{"name":34,"role":30,"phone":35,"phoneExt":10,"email":36},"Nora Monnier, Dr. med.","+41 61 284 82 29","nora.monnier@swisstph.ch",[38,54,64,74,90,100,115],{"facility":39,"status":40,"city":41,"state":10,"zip":10,"country":42,"countryCode":10,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Programme National de Lutte Contre les Maladies Tropicales Négligées à Chimiothérapie Préventive (PNLMTN-CP), Ministère de la Santé, de l'Hygiène Publique et de la Couverture Maladie Universelle (MSHPCMU)","RECRUITING","Abidjan","Côte d’Ivoire",{"type":44,"coordinates":45},"Point",[46,47],-4.00167,5.35444,{"lat":47,"lon":46},[50],{"name":51,"role":30,"phone":52,"phoneExt":10,"email":53},"Alain-Claver Kouamin, Dr. med.","+225 07 07 40 32 34","kouaminclaver@yahoo.fr",{"facility":55,"status":40,"city":41,"state":10,"zip":10,"country":42,"countryCode":10,"cosmosGeoPoint":56,"geoPoint":58,"contacts":59},"Université Félix Hophouët-Boigny (UFHB), Département de sociologie",{"type":44,"coordinates":57},[46,47],{"lat":47,"lon":46},[60],{"name":61,"role":30,"phone":62,"phoneExt":10,"email":63},"Alain Toh, Prof.","+225 07 07 14 63 46","alain.toh.1@gmail.com",{"facility":65,"status":40,"city":41,"state":10,"zip":10,"country":42,"countryCode":10,"cosmosGeoPoint":66,"geoPoint":68,"contacts":69},"Université Félix Hophouët-Boigny (UFHB), UFR Biosciences",{"type":44,"coordinates":67},[46,47],{"lat":47,"lon":46},[70],{"name":71,"role":30,"phone":72,"phoneExt":10,"email":73},"Eliézer K. N'Goran, Prof.","+225 01 03 48 88 83","eliezerngoran@yahoo.fr",{"facility":75,"status":76,"city":77,"state":10,"zip":10,"country":78,"countryCode":79,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"African Institute for Health and Development (AIHD)","NOT_YET_RECRUITING","Nairobi","Kenya","KE",{"type":44,"coordinates":81},[82,83],36.81667,-1.28333,{"lat":83,"lon":82},[86],{"name":87,"role":30,"phone":88,"phoneExt":10,"email":89},"Mary Amuyunzu-Nyamongo, Prof.","+254 733-366229","mnyamongo@aihdint.org",{"facility":91,"status":76,"city":77,"state":10,"zip":10,"country":78,"countryCode":79,"cosmosGeoPoint":92,"geoPoint":94,"contacts":95},"Kenya Medical Research Institute (KEMRI), Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC)",{"type":44,"coordinates":93},[82,83],{"lat":83,"lon":82},[96],{"name":97,"role":30,"phone":98,"phoneExt":10,"email":99},"Sammy M. Njenga, Prof.","+254 735-173372","SNjenga@kemri.go.ke",{"facility":101,"status":76,"city":102,"state":10,"zip":10,"country":103,"countryCode":104,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Makerere University, Department of Sociology and Anthropology","Kampala","Uganda","UG",{"type":44,"coordinates":106},[107,108],32.58219,0.31628,{"lat":108,"lon":107},[111],{"name":112,"role":30,"phone":113,"phoneExt":10,"email":114},"Stella Neema, Prof.","+256 772457576","sheisim@yahoo.com",{"facility":116,"status":76,"city":102,"state":10,"zip":10,"country":103,"countryCode":104,"cosmosGeoPoint":117,"geoPoint":119,"contacts":120},"Vector Borne & Neglected Tropical Disease Control Division, Ministry of Health",{"type":44,"coordinates":118},[107,108],{"lat":108,"lon":107},[121],{"name":122,"role":30,"phone":123,"phoneExt":10,"email":124},"Prudence Beinamaryo, Dr.","+256-789-548-930","prudenceb13@gmail.com",{"type":126,"investigatorFullName":127,"investigatorTitle":128,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Peter Steinmann","Unit Head",[130,133,135,137,139,142,144,146,148],{"name":131,"class":132},"Technical University Munchen","UNKNOWN",{"name":134,"class":6},"Makerere University",{"name":136,"class":132},"African Institute for Health and Development, Kenya",{"name":138,"class":6},"Kenya Medical Research Institute",{"name":140,"class":141},"Kenya Ministry of Health","OTHER_GOV",{"name":143,"class":141},"Ministry of Health, Uganda",{"name":145,"class":132},"Ministère de la Santé, de l'Hygiène Publique et de la Couverture Maladie Universelle",{"name":147,"class":132},"Université Félix Hophouët-Boigny",{"name":149,"class":132},"Unlimit Health","100569766","introduction-of-arpraziquantel-treatment-for-schistosomiasis-control-in-preschool-aged-children-in-endemic-areas-a-small-scale-public-health-intervention-study-100569766",false,"NCT06698510","Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: A Small-scale Public Health Intervention Study","Arpraziquantel for Schistosomiasis Control in Preschool-aged Children in Endemic Areas in Kenya and Côte d'Ivoire: A Small-scale Public Health Intervention Study Arpraziquantel for Schistosomiasis Control in Preschool-aged Children in Endemic Areas in Uganda, With Special Consideration of Dose Determination Methods: a Small-scale Public Health Intervention Study in Hoima and Bugiri Districts","ADOPTpilot","* Living in the designated implementation area since at least 6 months\n* Aged between 24 - 59 months\n* Informed consent available\n* No acute or chronic illness and\u002For inability to take oral medication\n* No reported history of seizures\n* No known allergic response to praziquantel",true,"ALL","24 Months","59 Months",{"count":163,"type":164},18500,"ESTIMATED","OBSERVATIONAL","The proposed small-scale pilot studies are public health intervention studies implemented through established routine programs and services in the frame of the mass drug administration (MDA) campaigns in Côte d'Ivoire, Kenya and Uganda. In each country two most promising health intervention platforms were selected for pilot distribution of arpraziquantel 150mg (arPZQ).\n\nThe aim of the small-scale pilot study is to assess the performance of different platforms for distributing arPZQ, a child-friendly formulation of praziquantel, to the target population (i.e., preschool-aged children (PSAC)) currently missed out in schistosomiasis treatment campaigns.\n\nThe specific objectives of the pilot study are:\n\n* To assess the performance of different platforms for delivery of arPZQ to PSAC aged 24 to 59 months in terms of coverage, feasibility and acceptability\n* To determine social mobilization and training needs for effective delivery of arPZQ through different platforms\n\nPreventive chemotherapy with arPZQ will be offered systematically to eligible PSAC aged 2 to below 5 years of consenting caregivers resident in the study area and reached through the selected platforms. Adverse events during MDA with arPZQ will be documented and reported by using existing tools and established reporting pathways aligned with standard pharmacovigilance and safety guidelines of the national drug authorities. Based on routine program processes and forms, variables pertaining to drug logistics, training, drug distribution, passive pharmacovigilance and supervision will be collected in order to measure and generate real-world data related to feasibility, coverage and acceptability of selected platforms and strategies to inform future scale-up to district levels.\n\nAssessments will take place before (to capture social mobilization and training activities) during and after the drug distribution to document the implementation process and evaluate experiences made by the different stakeholders (e.g. children, parents, community members, health workers, programme staff).",[168],"Schistosomiasis",[170,171,172,173,174,175,176],"schistosomiasis","preschool-aged children","praziquantel","arpraziquantel","deworming","pediatric treatment","child health","2025-09-19",{"date":179,"type":180},"2025-09-24","ACTUAL",{"date":182,"type":180},"2024-11-25",{"date":184,"type":164},"2026-03",{"name":127,"class":6},7]